BSD Medical Reports Findings from Study Sponsored by Terumo Europe N.V. Using MicroThermX® Microwave Ablation System
24 October 2014 - 2:15PM
Business Wire
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”),
a leading provider of medical systems that treat cancer and benign
diseases using heat therapy, announced today that Drs. JY Gaubert,
P Chevallier, and V Vidal, leading French researchers, presented
the successful results of their animal study utilizing the
MicroThermX® Microwave Ablation System (MicroThermX) at CIRSE 2014.
The study was sponsored by Terumo Europe N.V. The objective
of the study was to determine reproducibility of the ablation
volumes in liver and lung animal studies using the MicroThermX. The
researchers examined the results of 18 liver ablations and 24 lung
ablations and concluded that ablation volumes generated with the
MicroThermX were reproducible in in-vivo liver and lung
tissues.
“The positive results of this study reflect BSD’s and Terumo
Europe N.V.’s ongoing, long-term commitment to drive
innovation and expand treatment options for patients,” said Sam
Maravich, Vice President of International Sales and Marketing at
BSD Medical. “This study, and others to follow, could help pave the
way for our MicroThermX system to be adopted by hospitals and
treatment centers all over the world. Microwave ablation therapy
has the potential to improve treatment outcomes and quality of life
for patients.”
The study, “In vivo experimental evaluation of ablation volumes
obtained by microwave in the lung and liver with MicroThermX,” was
conducted by the Department of Adult Radiology at Timone University
in Marseille, France; the Department of Radiology at University
Hospital L’Archet in Nice, France; and the Laboratory of
Experimental and Interventional Imagining at Aix-Marseille
University, leading research institutions in France.
About the MicroThermX® Microwave Ablation
System
The MicroThermX is a compact, mobile, state-of-the-art,
proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based
temperature monitoring system. The innovative design of the
MicroThermX is the first of its kind that allows delivery of higher
power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array
technology that was developed and patented by MicroThermX BSD to
provide a wide range of uniform zones of ablation. The MicroThermX
includes innovative, high-end disposables (SynchroWave antennas)
that are used in each ablation treatment and will provide a
significant ongoing revenue stream.
The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX for ablation
of soft tissue. BSD has also received CE Marking for the
MicroThermX System, which allows BSD to market the MicroThermX in
Europe. CE Marking is also recognized in many countries outside of
the EU, providing BSD the ability to market the MicroThermX to a
number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy delivered using focused microwave energy and radiofrequency
(RF). BSD’s product lines include ablation and hyperthermia
treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market, and well established distribution
in the United States, Europe and Asia. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors
with heat (hyperthermia) while increasing the effectiveness of
other therapies such as radiation therapy. Certain of the Company’s
products have received regulatory approvals in the United States,
Europe and China. For further information visit BSD Medical’s
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our 2015 plans,
are forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties detailed in the
Company’s filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the
regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date, except as
required by law.
For BSD Medical CorporationTricia Ross,
310-622-8226investor@bsdmc.com